Clinical Trial

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-10-31 -> 2028-12-11 2026-07-08
minor Completion pushed: 2028-10-31 -> 2028-12-11 2026-07-08
Trial Details
NCT Number NCT07117214
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
Enrollment 36 participants
Start Date 2026-06-26
Primary Completion 2028-12-11 (estimated)
Study Completion 2028-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-07